Category: Top Story
-
U.S. stocks tumble as oil rally fueled by Middle East conflict rattles markets
U.S. equities opened sharply lower on Monday as escalating tensions in the Middle East pushed oil prices toward $100 a barrel, intensifying concerns that rising energy costs could pressure economic growth. As of 09:43 ET, the S&P 500 declined 1.2% to 6,655.57, the Nasdaq Composite dropped 1.3% to 22,103.06, and the Dow Jones Industrial Average…
-
Amazon Pharmacy launches Zepbound KwikPen with $299 monthly starting price
Amazon Pharmacy (NASDAQ:AMZN) said it has begun offering Eli Lilly’s Zepbound KwikPen, a multi-dose injectable medication for weight management, with cash-pay pricing starting at $299 per month for the 2.5 mg introductory dose, according to a company press release. The offering further expands Amazon’s growing presence in healthcare as the $2.29 trillion company continues broadening…
-
Oracle refutes reports of issues at Abilene AI data center
Oracle Corporation (NYSE:ORCL) rejected recent media claims suggesting problems at its major AI data center in Abilene, Texas, saying the project remains on schedule and that it has secured the full 4.5 gigawatts of capacity pledged to OpenAI. Despite the clarification, Oracle shares were down 1.2% at $152.96 in pre-market trading, reflecting broader weakness across…
-
Five key themes for markets in the week ahead
The conflict involving Iran continues to intensify at the start of the new week, pushing oil prices above $100 per barrel and fueling concerns about renewed global inflation pressures. At the same time, the Federal Reserve has entered its policy blackout period as a series of important inflation and labor market data releases approach. On…
-
Pfizer shares slip despite encouraging trial results for eczema treatment
Pfizer Inc (NYSE:PFE) shares declined 1.15% to $26.74 in premarket trading Monday, even after the pharmaceutical company reported positive mid-stage clinical trial results for its experimental antibody therapy targeting atopic dermatitis. The drugmaker said the antibody, tilrekimig, showed meaningful improvement in symptoms of the chronic inflammatory skin condition during the study. According to Pfizer, a…
-
Hims surges 44% after report Novo Nordisk may offer weight-loss drugs on its platform
Novo Nordisk (NYSE:NVO) is planning to distribute its weight-loss medications through the telehealth platform operated by Hims & Hers Health (NYSE:HIMS), signaling an unexpected thaw in relations between the companies after a recent legal clash, Bloomberg reported over the weekend. Shares of Hims — which have fallen roughly 51% so far this year — jumped…
-
Yardeni warns meltdown risk rising as Polymarket recession odds climb to 37%
Expectations of a U.S. recession have risen notably since the escalation of conflict in the Middle East, as investors grow more concerned about the economic consequences of higher energy prices and geopolitical instability. U.S. stock futures were lower in early Monday trading, with S&P 500 futures declining 1.4%. Data from prediction platform Polymarket shows the…
-
Live Nation nears settlement in U.S. antitrust case without selling Ticketmaster, report says
Live Nation Entertainment (NYSE:LYV) is reportedly approaching a settlement with U.S. regulators in a federal antitrust lawsuit that could allow the company to keep its Ticketmaster division, according to a Bloomberg News report on Monday citing people familiar with the matter. The U.S. Department of Justice and more than two dozen states filed the lawsuit…
-
Uranium ensures energy sovereignty: How investors can profit with Stallion Uranium, NexGen Energy, and Constellation Energy – which stock is the favourite?
In times of war, uranium rises from a cyclical commodity to a strategic asset. Even in Germany, people are aware of the dilemma that the energy policy of recent years has maneuvered them into: either they are dependent on imports, or they have to think more openly about technology, for example, nuclear power. The Canadian…
-
Billion-Dollar Opportunity from the NDAA: NEO Battery Materials benefits from the US shift away from Chinese supply chains
In the world of battery startups, the path from promising laboratory formula to a delivered product is fraught with pitfalls. Technology promises fizzle out, production ramp-ups stall, and customers walk away. It is a business where confidence can quickly evaporate. This makes the development of a Canadian company based in Toronto over the past few…